Skip to main content

Table 2 Profiles of the patients in the control group

From: Change in muscle volume after steroid therapy in patients with myositis assessed using cross-sectional computed tomography

Patient Age (years) Sex Diagnosis Max glucocorticoid (mg/day)a Duration between the start of treatment and second CT (months)b Dose of glucocorticoid at second CT (mg/day) Cumulative doses of glucocorticoid (g)c,d
1 70 M MCNS PSL: 40 1.5 PSL: 25 PSL: 1.4
2 66 F LN mPSL → PSL: 35 2.5 PSL: 20 PSL: 2.4
3 46 F LN mPSL → mPSL: 32 3 mPSL: 12 PSL: 2.2
4 57 F EPGA mPSL → PSL: 50 3 PSL: 25 PSL: 3.4
5 80 M MPA mPSL → PSL: 30 2.5 PSL: 15 PSL: 1.3
6 86 F MPA mPSL → mPSL: 32 1.5 mPSL: 20 PSL: 1.5
7 79 F MCNS mPSL: 32 1.5 mPSL: 16 + PSL: 2 PSL: 1.6
8 76 F HSPN mPSL: 32 5.0 mPSL: 8 PSL: 2.6
  1. M male, F female, MCNS minimal change nephrotic syndrome, LN lupus nephritis, EPGA eosinophilic granulomatosis with polyangiitis, MPA microscopic polyangiitis, HSPN Henoch-Schönlein purpura nephritis, PSL prednisolone, mPSL methylprednisolone
  2. aInitial mPSL dose was 500 mg × 3 d, except for Patient 3 (1 g × 3 d) and Patients 7 and 8 (reported in table)
  3. bThe first CTs were performed within 6 weeks before the initial steroid therapy
  4. cSteroid taken using steroid pulse was excluded from cumulative doses of glucocorticoid
  5. dmPSL 0.8 mg is converted as PSL 1 mg